Table 1.
Comprehensive overview on cliniconeuropathologic correlations
| CA versus AVMa | Gendera | Age at seizure onset >30 yearsa | Seizure frequency ≥6 versus ≤2 seizures/montha,b | Disease duration >20 yearsa | Outcome Engel III/IV versus Engel Ia | Hemosiderin abundant versus none/fewa | Albumin in astrocytesb,c | |
|---|---|---|---|---|---|---|---|---|
| CA versus AVMa | – | 1.000 | 0.367 | 1.000 | 1.000 | 0.496 | 0.046 | 0.396 |
| Gendera | – | 1.000 | 0.637 | 1.000 | 0.777 | 1.000 | 0.644 | |
| Age at seizure onset >30 yearsa | – | 1.000 | 0.026 | 0.582 | 0.087 | 0.177 | ||
| Seizure frequency ≥6 versus ≤2 seizures/montha,b | – | 0.577 | 0.294 | 1.000 | 0.300 | |||
| Disease duration >20 yearsa | – | 0.015 | 0.542 | 0.898 | ||||
| Outcome Engel III/IV versus Engel Ia | – | 0.377 | 0.964 | |||||
| Hemosiderin abundant versus none/fewa | – | 0.702 |
CA, cavernous angioma; AVM, arteriovenous malformation. Bold indicates p < 0.05.
a
Fisher’s two-sided exact test.
b
Detailed preoperative seizure frequency was obtained and analyzed in the representative patient group selected for albumin-immunohistochemistry (n = 27).
c
Unpaired t-test.